Drug: Mircera
Indication: Anemia
Company: Roche
Approval Date: November 14, 2007

Scoop: Mircera has a longer half-life than other commercially available erythropoiesis-stimulating agents (ESA). However, Roche lost a patent infringement case to Amgen, which markets the bestselling--and controversial--anti-anemia drugs Aranesp and Epogen. Though Mircera is available overseas, for the forseeable future it will not be marketed in the U.S.

More news:
Mircera gets FDA nod, but blocked by patent case. Report [0]
Roche: Patent ruling won't stop Mircera. Report [1]
Roche to Launch Mircera in UK and Germany. Report [2]